Overview

Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation.

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
To compare the efficacy and safety of two regimens containing tacrolimus and minimal steroids together with either monoclonal anti-IL2R antibodies (daclizumab) or mycophenolate mofetil.
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Antibodies
Tacrolimus